<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03800017</url>
  </required_header>
  <id_info>
    <org_study_id>H18-02059</org_study_id>
    <nct_id>NCT03800017</nct_id>
  </id_info>
  <brief_title>Skeletal Muscle Function in Interstitial Lung Disease</brief_title>
  <official_title>Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with&#xD;
      interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle&#xD;
      dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i)&#xD;
      examine differences in the structure and function of the leg muscles in ILD patients, ii)&#xD;
      determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients&#xD;
      with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as&#xD;
      well as ability to exercise in ILD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE:&#xD;
&#xD;
      The primary purpose of the proposed work is to characterize skeletal muscle function in&#xD;
      patients with interstitial lung disease (ILD), and to determine the physiological and sensory&#xD;
      consequences of impaired skeletal muscle function in ILD during exercise.&#xD;
&#xD;
      HYPOTHESES:&#xD;
&#xD;
      The hypotheses are threefold; i) patients with ILD will have impaired skeletal muscle&#xD;
      function when compared to healthy controls, ii) impairments in skeletal muscle function&#xD;
      predispose ILD patients to exercise-induced quadriceps muscle fatigue, increase the&#xD;
      perception of exertional dyspnea, as well as reduce exercise tolerance, and iii) delivery of&#xD;
      supplemental oxygen during exercise mitigates exercise-induced quadriceps muscle fatigue,&#xD;
      attenuates the perceived intensity of dyspnea, and improves exercise tolerance.&#xD;
&#xD;
      OBJECTIVE:&#xD;
&#xD;
      The objective of the proposed study is to comprehensively investigate skeletal muscle&#xD;
      dysfunction in patients with ILD and characterize its impact on dyspnea and exercise&#xD;
      tolerance. In doing so, the proposed work will be the first to comprehensively assess&#xD;
      skeletal muscle function in patients with ILD as well as determine its functional&#xD;
      consequences. The results will provide important insight into the putative role of skeletal&#xD;
      muscle dysfunction on exercise limitation in patient with ILD.&#xD;
&#xD;
      JUSTIFICATION:&#xD;
&#xD;
      ILD refers to a diverse group of diseases that share common physiological characteristics&#xD;
      resulting from inflammation and/or fibrosis of the lung parenchyma. ILD has an estimated&#xD;
      prevalence of approximately 67-81 cases per 100 000 individuals. Given the heterogeneity of&#xD;
      disease sub-types, it is difficult to determine a precise median survival for patients with&#xD;
      ILD, however; in patients with idiopathic pulmonary fibrosis, the most common ILD sub-type,&#xD;
      have a median survival of only 2-3 years from the time of diagnosis. For patients with ILD,&#xD;
      dyspnea (i.e. breathlessness) is the most common symptom. Dyspnea can be extremely&#xD;
      debilitating, particularly during physical exertion. The clinical significance of dyspnea in&#xD;
      ILD is underscored by its strong correlation with quality of life and mortality. Patients&#xD;
      attempt to minimize dyspnea by avoiding physical activity, resulting in deconditioning and an&#xD;
      associated reduction in functional capacity. The importance of maintaining functional&#xD;
      capacity is highlighted by the fact that ILD patients with the lowest physical activity&#xD;
      levels have the lowest quality of life and the highest mortality. The effective management of&#xD;
      dyspnea and exercise intolerance is therefore of critical importance when considering the&#xD;
      management of patients with ILD.&#xD;
&#xD;
      The pathophysiological mechanisms of dyspnea and exercise intolerance in ILD are complex,&#xD;
      multifactorial, and poorly understood. Indeed, relatively few studies that have adequately&#xD;
      investigated the mechanistic basis of dyspnea and exercise intolerance in patients with ILD.&#xD;
      It is generally agreed upon that exercise limitation in ILD is related to the combination of&#xD;
      altered respiratory mechanics, gas exchange impairment, and circulatory limitation. However,&#xD;
      it is assumed that dyspnea and exercise intolerance are exclusively related to the&#xD;
      respiratory and circulatory impairment associated with the pathogenesis of ILD. While this&#xD;
      assumption is reasonable, it ignores the potentially crucial role of skeletal muscle&#xD;
      dysfunction as a source of dyspnea and exercise intolerance. Recent experimental evidence&#xD;
      indicates that skeletal muscle dysfunction contributes to both dyspnea and exercise&#xD;
      intolerance in COPD.&#xD;
&#xD;
      A growing body of literature supports the notion that skeletal muscle dysfunction is common&#xD;
      in ILD. While the precise mechanisms remain unclear, several well-established skeletal muscle&#xD;
      dysfunction-promoting factors are present in many ILD patients, including: chronic&#xD;
      hypoxaemia, oxidative stress, pulmonary and systemic inflammation, physical deconditioning,&#xD;
      malnutrition, and corticosteroid use. These factors may act individually or synergistically&#xD;
      to impair skeletal muscle function by causing muscle atrophy, mitochondrial dysfunction, a&#xD;
      reduction in type I muscle fibre proportion, and increases in intramuscular fat. To our&#xD;
      knowledge, there is limited imaging data of skeletal muscle morphology in ILD, and&#xD;
      assessments of skeletal muscle oxidative capacity, and contractile function have not been&#xD;
      concurrently obtained. If present, skeletal muscle dysfunction likely reduces locomotor&#xD;
      muscle oxidative capacity, leading to premature fatigue, increased dyspnea, and diminished&#xD;
      exercise tolerance. Most importantly, there is no data on the physiological effects of&#xD;
      skeletal muscle fatigue and dysfunction on dyspnea and exercise capacity nor whether targeted&#xD;
      treatment options such as supplemental oxygen (O2) delivery can attenuate muscle fatigue.&#xD;
&#xD;
      Accordingly, the aims of the proposed research are threefold: i) to characterize skeletal&#xD;
      muscle function in patients with ILD compared to healthy controls, ii) to determine the&#xD;
      influence of skeletal muscle dysfunction on dyspnea, fatigue, and exercise intolerance in&#xD;
      patients with ILD compared to healthy controls, and iii) to determine if improving exercise&#xD;
      tolerance using supplemental oxygen relieves exercise-induce skeletal muscle fatigue in ILD&#xD;
      patients.&#xD;
&#xD;
      RESEARCH DESIGN:&#xD;
&#xD;
      Experimental hypotheses tested using combination of research designs. To test the hypotheses&#xD;
      i) and ii), the investigators will use a cross sectional design. To test hypothesis iii), the&#xD;
      investigators will use a single-blind placebo-controlled study design.&#xD;
&#xD;
      METHODS Participants will report to the laboratory on four separate occasions separated by a&#xD;
      minimum of 48 hours, and each visit will last ~2-3 hours.&#xD;
&#xD;
      Visit 1:&#xD;
&#xD;
      Participants will complete medical history screening, complete a series of questionnaires&#xD;
      concerning chronic activity-related dyspnea, quality of life, and physical activity.&#xD;
      Participants will then have their height and weight measured and perform pulmonary function&#xD;
      testing. Finally, participants will perform a symptom limited incremental cycle exercise&#xD;
      test. Detailed physiological and sensory measurements will be obtained immediately before and&#xD;
      throughout the incremental cycle exercise test.&#xD;
&#xD;
      Visit 1 will be intended to characterize participant's pulmonary function and exercise&#xD;
      capacity.&#xD;
&#xD;
      Visit 2:&#xD;
&#xD;
      Participants will undergo a magnetic resonance imaging scan to assess the volume and the fat&#xD;
      percentage of their quadriceps muscles They will then perform a series of tests aimed at&#xD;
      evaluating their quadriceps muscle function, including: i) assessment of maximum voluntary&#xD;
      quadriceps muscles strength, and ii) the non-invasive assessment of the oxidative capacity of&#xD;
      their quadriceps muscle using near-infrared spectroscopy.&#xD;
&#xD;
      Data from visit 2 will be used to address hypothesis 1 by characterizing participant's&#xD;
      quadriceps muscle function.&#xD;
&#xD;
      Visits 3:&#xD;
&#xD;
      Participants will perform a constant-load exercise test to exhaustion while breathing ambient&#xD;
      air (i.e., 20.93% oxygen). The work load will be set at 75% of the highest work rate achieved&#xD;
      during the incremental exercise test performed during visit 1.&#xD;
&#xD;
      Data from visits 3 and 4 will be used to address hypothesis 2 by characterizing the effect of&#xD;
      exercise on skeletal muscle fatigue in patients with ILD and healthy controls.&#xD;
&#xD;
      Visit 4:&#xD;
&#xD;
      Participants will perform a constant-load exercise test while breathing supplemental oxygen&#xD;
      (i.e., 60% oxygen). The work load will be set at 75% of the highest work rate achieved during&#xD;
      the incremental exercise test performed during visit 1 and the test will be terminated once&#xD;
      participants reach the same time that they achieved during the constant-load exercise test on&#xD;
      Day 3.&#xD;
&#xD;
      Data from visit 4 will be used to address hypothesis 3 by determining if supplemental oxygen&#xD;
      can be used to alleviate exercise-induced skeletal muscle fatigue in patients with ILD and&#xD;
      healthy controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2022</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in standardized dyspnea score during the constant load exercise test (visit 3)</measure>
    <time_frame>Dyspnea will be measured once every minute during exercise on visit 3 (up to 7 weeks after baseline) until participants reach volitional exhaustion (assessed for up to 30 minutes)</time_frame>
    <description>Dyspnea rating, measured using the Borg 0-10 category ratio scale, will be assessed every 1 minute during the constant-load exercise test on visit 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in standardized dyspnea score during the constant load exercise test (visit 4)</measure>
    <time_frame>Dyspnea will be measured once every minute during exercise on visit 4 (up to 8 weeks after baseline) until participants reach volitional exhaustion (assessed for up to 30 minutes)</time_frame>
    <description>Dyspnea rating, measured using the Borg 0-10 category ratio scale, will be assessed every 1 minute during the constant-load exercise test on visit 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in leg muscle strength measured following the constant load exercise test (visit 3)</measure>
    <time_frame>Leg muscle strength will be measured before and after exercise (assessed for up to 40 minutes) on visit 3 (up to 8 weeks after baseline)</time_frame>
    <description>Leg muscle strength will be measured before (at rest) and 3 min after the constant-load exercise test on visit 3 using the femoral magnetic stimulation technique.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in leg muscle strength measured following the constant load exercise test (visit 4)</measure>
    <time_frame>Leg muscle strength will be measured before and after exercise (assessed for up to 40 minutes) on visit 4 (up to 8 weeks after baseline)</time_frame>
    <description>Leg muscle strength will be measured before (at rest) and 3 min after the constant-load exercise test on visit 4 using the femoral magnetic stimulation technique.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quadriceps muscle oxidative capacity measured using near-infrared spectroscopy</measure>
    <time_frame>On visit 2, approximately 3 weeks post-baseline (visit 1)</time_frame>
    <description>Quadriceps muscle oxidative capacity will measured using near-infrared spectroscopy. Parameters will be measured over 5 minutes once on visit 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quadriceps muscle volume measured using magnetic resonance imaging</measure>
    <time_frame>On visit 2, approximately 3 weeks post-baseline (visit 1)</time_frame>
    <description>Quadriceps muscle volume will be measured using magnetic resonance imaging. Parameters will be measured over 15 minutes once on visit 2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Hypersensitivity Pneumonitis</condition>
  <condition>Scleroderma</condition>
  <condition>Nonspecific Interstitial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Hyperoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During exercise on visit 4, participants in both groups (i.e., ILD patients and controls) will breathe supplemental oxygen (i.e., 60% oxygen) during constant-load exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During exercise on visit 3, participants in both groups (i.e., ILD patients and controls) will breathe ambient air (i.e., 20.93% oxygen) during constant-load exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hyperoxia</intervention_name>
    <description>Participants breathe 60% oxygen during exercise</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Hyperoxia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for ILD Patients:&#xD;
&#xD;
          -  Age 40-80 years (inclusive)&#xD;
&#xD;
          -  A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic&#xD;
             fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity&#xD;
             pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of&#xD;
             the above diagnoses&#xD;
&#xD;
          -  Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or&#xD;
             traction bronchiectasis&#xD;
&#xD;
          -  Appropriate candidate for pulmonary rehabilitation&#xD;
&#xD;
          -  6 minute walk distance 50m or more&#xD;
&#xD;
          -  Oxygen saturation â‰¥ 92% by pulse oximetry at rest while breathing room air&#xD;
&#xD;
          -  Clinically stable for the preceding 6 weeks&#xD;
&#xD;
          -  Can fluently read and write in English&#xD;
&#xD;
        Inclusion Criteria for Healthy Controls:&#xD;
&#xD;
          -  Age 40-80 (inclusive)&#xD;
&#xD;
          -  Normal pulmonary function (80-120% predicted)&#xD;
&#xD;
          -  No lung or cardiovascular disease&#xD;
&#xD;
          -  Can fluently read and write in English&#xD;
&#xD;
        Exclusion Criteria for the ILD patients:&#xD;
&#xD;
          -  Contraindication to exercise testing (e.g. significant cardiovascular,&#xD;
             musculoskeletal, neurological disease)&#xD;
&#xD;
          -  Other significant extra-pulmonary disease that, based on clinical assessment, could&#xD;
             impair exercise capacity and/or oxygenation&#xD;
&#xD;
          -  Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide&#xD;
             (DLCO) less than 25%&#xD;
&#xD;
          -  Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation&#xD;
             program&#xD;
&#xD;
          -  Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the&#xD;
             first study visit&#xD;
&#xD;
          -  Significant emphysema (less than 10% volume on HRCT or FEV1/FVC less than 0.70)&#xD;
&#xD;
        Exclusion Criteria for Healthy Controls:&#xD;
&#xD;
          -  Currently smoking or previously smoked more than 10 pack-years&#xD;
&#xD;
          -  Any medical conditions that prevents them for exercising safely&#xD;
&#xD;
          -  Cardiac pacemaker or any metal or electronic inside the body&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan A Guenette, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yannick Molgat-seon, PhD</last_name>
    <phone>1-604-682-2344</phone>
    <phone_ext>63258</phone_ext>
    <email>yannick.molgat-seon@hli.ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Satvir S Dhillon, MSc</last_name>
    <phone>1-604-806-8835</phone>
    <email>Satvir.Dhillon@hli.ubc.ca</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2019</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jordan Guenette</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Alveolitis, Extrinsic Allergic</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

